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Abstract
Objective: To investigate the impact of pseudoxanthoma elasticum (PXE), a rare hereditary disease of concurrent
vision impairment (VI) and cardiovascular complications (CVCs), on vision-related (VRQoL) and health-related quality
of life (HRQoL).
Methods: VRQoL and HRQoL were assessed using the Impact of Vision Impairment (IVI) questionnaire and the
Short Form Health Survey (SF-36) in 107 PXE patients. Patients were stratified into four groups: A = no VI or CVC; B
= CVCs only; C = VI only; and D = both VI and CVCs.
Results: Following Rasch analysis, the IVI was found to function as a vision-specific functioning and emotional
well-being subscale, and the SF-36 as a health-related physical functioning and mental health subscale. The
presence of VI and CVC were significant predictors of vision-specific functioning and emotional well-being (p <
0.001), with a clinically meaningful decrement in vision-specific functioning in patients with VI. No associations
were found for the SF-36 Physical Functioning and Mental Health scores between any groups.
Conclusions: Vision impaired patients with PXE report significantly poorer vision-specific functioning than PXE
patients without VI. In contrast, the relative impact of PXE on reported general HRQoL was much less. Our results
suggest that vision impairment has the larger impact on QoL in this sample.
Keywords: Vision-related quality of life (VRQoL), health-related quality of life (HRQoL), visual impairment, cardiovas-
cular disease, Pseudoxanthoma elasticum (PXE), Impact of Vision Impairment Questionnaire (IVI), SF-36
Introduction
Pseudoxanthoma elasticum (PXE) is a rare, hereditary,
autosomal recessive disease [1]. PXE is characterized by
a systemic calcification of elastic tissue affecting fore-
most the skin, the ocular fundus and the cardiovascular
system. Cardiovascular manifestations of PXE include
arterial hypertension, peripheral arterial disease, angina
pectoris, restrictive cardiomyopathy, mitral valve pro-
lapse or stenosis, and sudden cardiac failure, often
resulting in death [2-7]. PXE also affects the ocular fun-
dus due to a centrifugal alteration of Bruch’s membrane
[1,8]. This eventually leads to breaks in Bruch’s
membrane which may appear clinically as angioid
streaks [9], predisposing the patient to the development
of choroidal neovascularisations (CNVs). These second-
ary angiogenic processes usually occur as early as the
third or fourth decade of life, leading to the vast major-
ity of patients being legally blind in their fifth or sixth
decade [1].
Vision impairment (VI) and cardiovascular complica-
tions (CVCs) have been shown to adversely affect daily
functioning and other aspects of quality of life (QoL)
[10-14]. Consequently, it can be hypothesised that PXE
patients, who have both VI and CVCs, will experience
poor vision-related (VRQoL) and health-related quality
of life (HRQoL). However, to date no attempt has been
made to quantify the VRQoL or HRQoL impact of PXE
from the patient’s perspective. Similarly, it remains
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and CVCs on VRQoL or HRQoL is similar, or whether
one is more detrimental than the other. This informa-
tion is essential for rehabilitation workers and policy
planners to develop optimal services and resources.
Therefore, we investigated the magnitude of the
impact of PXE on VRQoL and HRQoL using the Impact
of Vision Impairment questionnaire (IVI)[15,16] and the
Short Form Health Survey (SF-36)[17,18], respectively,
in a sample of PXE patients with differing levels of VI
and CVCs.
Methods
Patients
A total of 198 German patients with PXE were sent a
postal survey in 2008 using the mailing list of the Ger-
man PXE Patient Association, of whom 135 returned
completed questionnaires (response rate 68%). Each par-
ticipant received the IVI and SF-36 questionnaires; a
short questionnaire assessing the patients’ sociodemo-
graphic characteristics and medical history; and a con-
sent form. Self-reported medical history, including
ophthalmic history, was validated against available
responding patients’ files known to the department of
ophthalmology at the University of Bonn (n = 82).
Based on very limited data available, respondents and
non-respondents seemed no different. However, too lim-
ited data was available for non-responders to allow for a
statistical comparison. Ethical approval was obtained
from the ethics committee of the University of Bonn.
All patients consented to partaking in the study. The
study adhered to the tenets of the declaration of
Helsinki.
Quality of life outcome measures
Impact of Vision Impairment (IVI)
The IVI questionnaire is a vision-specific instrument
which measures the impact of vision impairment on var-
ious QoL parameters and was developed using focus
group discussions and input from existing instruments
[19]. The IVI contains 28 items with 4-5 response
options using Likert scaling, ranging from ‘n o ta ta l l ’ to
‘can’t do because of eye sight’. Items form three specific
subscales: ‘reading and accessing information’, ‘mobility
and independence’ and ‘emotional well-being’.T h eI V I
has been shown to be reliable, [20] responsive to inter-
ventions [16] and it has been rigorously validated using
modern psychometric methods such as Rasch analysis
for different ocular conditions as well as levels of visual
impairment [15,16,21]. The psychometric properties of
the German IVI have recently been evaluated by our
group using Rasch analysis and it was found to be a
valid and reliable outcome measure to assess VRQoL
[22].
Short Form Health Survey (SF-36)
The SF-36 is a generic health-related QoL tool which
has been validated across a number of populations with
various conditions, both chronic and acute [17,23-25].
The SF-36 measures eight dimensions of health and
well-being using 36 items which are coded, summated
and transformed to yield eight subscales. These can be
further reduced into two domains, namely the physical
and mental component score. The German version has
been thoroughly validated and used to collect normative
data across a broad spectrum of health states, including
healthy controls [18,26,27].
Psychometric Validation of the IVI and the SF-36
Rasch analysis is a modern psychometric technique that
calculates person ability in relation to item difficulty by
placing them on the same linear continuum. Rasch ana-
lysis provides insight into the psychometric properties of
a scale, such as its reliability and overall fit to the
model, the appropriateness of the response scale used,
unidimensionality, targeting of the scale to the sample
involved, and individual item fit and item bias. In Rasch
analysis, raw ordinal scores are transformed into esti-
mates of interval-level measurement (expressed in log of
the odds units, or logits). A high logit score indicates
that a person possesses a high level of the assessed
latent trait (e.g. VRQoL). To ease interpretation, the rat-
ing scale of the IVI was reversed for Rasch analysis so
that patients with a high level of VRQoL were given
high scores. The rating scale for the SF-36 items was
not reversed as the most able participants were already
allocated the highest score.
Rasch analysis was undertaken using the Andrich rat-
ing scale model [28] with Winsteps software (version
3.68), Chicago, Illinois, USA [29] to validate both the
IVI and the SF-36. Several key indicators of each scale
were examined. We assessed the response category
threshold ordering by visually checking for disordered
thresholds. Disordered thresholds may result when a
category is underused, category definition is unclear, or
when participants have difficulty discriminating between
response options. Disordered thresholds can cause sig-
nificant item and model misfit and collapsing response
categories may be necessary to improve model fit. The
discriminant ability of the scale was determined using
the person separation index (PSI) and person reliability
(PR) values which measure the ability of the scale to dis-
tinguish distinct levels of participant ability. A PSI of 2.0
and a person reliability score of 0.8 represent three dis-
tinct levels of participant ability [30]. Targeting of item
difficulty to participant ability is assessed by inspecting
the person-item map, where the person and item mea-
sures are displayed on the same calibration ruler. Effec-
tive targeting is evident when the person and item
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value is zero [31].
Rasch analysis requires that a scale measures a single
underlying trait, or that it is unidimensional. Thus we
tested all conventional subscales for the IVI and SF-36
as well as summary scores. Two parameters are used to
assess scale unidimensionality: item ‘fit statistics’ and
testing the assumption of local independence. Item fit
determines how well each item fits the underlying trait,
e.g., VRQoL and items with an infit mean square value
(MNSQ) ranging between 0.7 and 1.3 were considered
acceptable. The primary component analysis (PCA) of
the residuals was examined to test for local indepen-
dence. The variance explained by the Rasch measures
for the empirical calculation should be comparable to
that of the model (> 50% for an acceptable model).
Furthermore, the unexplained variance by the residuals
in the first contrast should be < 2.4 eigenvalue units
which is close to that seen with random data. Finally,
we assessed for differential item functioning (DIF) which
indicates whether different groups within the sample (e.
g. gender, age) systematically respond differently despite
equal levels of the trait being assessed. A DIF contrast
of > 1.0 logits for an item was considered to represent
notable DIF and to indicate possible interpretation bias
for that item.
Statistical Analysis
The SPSS statistical software (Version 17.0, SPSS
Science, Chicago, IL) was used to analyze the data.
Patients were stratified into four groups according to
their clinical characteristics, namely Group A = no VI
and no CVC (n = 16); Group B = CVCs only (n = 35);
G r o u pC=V Io n l y( n=1 5 ) ;a n dG r o u pD=b o t hV I
and CVCs (n = 41). Descriptive statistical analyses were
performed to characterize the participants’ sociodemo-
graphic, clinical, IVI and SF-36 data using univariate
analyses of variance for continuous variables and multi-
nomial logistic regression for categorical variables. Func-
tional and emotional domain scores of both HRQoL and
VRQoL were the main outcomes. Following Rasch ana-
lyses, the overall and individual person scores were
obtained as linear estimates, which then were fitted to
regression models. The association between VRQoL and
HRQoL (overall and specific aspects of) and PXE was
analysed using regression models, adjusting for covari-
ables that were found to be univariately associated with
the main outcomes i.e. age, gender and visual impair-
ment. Partial eta-squared which is a measure of effect
size was used to describe the strength of the association
between a predictor (or set of predictors) and the
dependent variable. It can be characterized as the pro-
portion of total variation attributable to the factor,
partialling out (excluding) other factors from the total
nonerror variation [32].
Twenty-eight patients were removed from the final
analyses as they were without vision or general impair-
ment data or too able for the questionnaires as evident
by a ceiling effect in their item responses. As with all
questionnaires, those participants experiencing little dis-
ability from the assessed health condition may find the
questions very easy - in other words the questions are
too easy for very able participants. This can affect the
targeting of the questionnaire, meaning that the mean
difficulty of the items does not effectively match the
mean ability of the participants. Thus, by removing the
most able participants from the analysis the targeting,
and consequently the overall functioning of the scale,
improves. This resulted in a final sample size of 107
participants. Sample size required by Rasch analysis is
calculated by items per questionnaire times 5 responders
for a validation study. As both questionnaires have been
previously validated in German, the slightly smaller sam-
ple size than no. of items × 5 in this study can still be
considered sufficient, in particular considering the rarity
of PXE [33].
Results
Sample Characteristics
T h em a j o r i t yo ft h es a m p l ew a sf e m a l e( n=6 8 ,6 3 % ;
Table 1). The mean ± SD age and best corrected visual
acuity values were 57 ± 12 years and 0.79 ± 0.67 Log-
MAR, respectively. Patientsh a d ,o na v e r a g e ,1 . 6C V C s
with hypertension, peripheral arterial disease and coron-
ary heart disease being most common. Over forty per-
cent of the patients (n = 45, 42%) needed help filling
out the questionnaires. After splitting the sample into
four groups, patients with VI and CVCs (group D) were
significantly older than the other groups (all p≤0.05) and
patients with VI (groups C & D) needed more help to
fill in their questionnaires (all p≤0.01). The unequal gen-
der distribution (63% women) was similar across all four
subgroups (p > 0. 05).
Psychometric evaluation of the German IVI and SF-36
Psychometric properties of the IVI
The data for the German-translated IVI were fitted to
the Rasch model and several indicators of fit were
explored (Table 2). There was evidence of disordered
thresholds which necessitated categories 1 and 2 (’a fair
amount’ and ‘a little’) to be collapsed, resulting in
ordered thresholds for all items. The PSI and the PR
values were 4.07 and 0.94, respectively, which indicates
that the scale was able to discriminate between five
strata of VRQoL. The targeting of the instrument was
acceptable (difference in person and item means 1.15
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ality in the scale. Although the raw variance explained
by the PCA of the residuals was adequate (64.2%), the
unexplained variance in the first contrast of the resi-
duals was 3.9, suggesting the existence of a second
dimension. Moreover, four items (Items 21, 22, 25, 26)
demonstrated misfit (MNSQ > 1.3). All four of these
items belonged to the ‘emotional well-being’ domain
and their standardized residual loadings were all > 0.4
units suggesting that they were loading onto the same
construct. Removal of these items did not improve the
overall fit statistics. Therefore, the IVI was split into a
Functional Scale (Items 1-20) and Emotional Scale
(Items 21-28) which resulted in both scales fitting the
Rasch model (Table 3).
The Functioning Scale had excellent discriminant abil-
ity, no misfitting items, and minimal evidence of multi-
dimensionality with the PCA for the first factor
explaining > 60% of the variance and the first contrast
of the residuals being acceptable (2.4 eigenvalues). Tar-
geting was suboptimal (difference in person and item
mean 1.25) which may suggest that the patients in this
Table 1 Sociodemographic and clinical characteristics of the 107 patients with PXE.
Total sample
(n = 107)
Group A
(n = 16)
No VI or CVCs
Group B
(n = 35)
Only CVCs
Group C
(n = 15)
Only VI
Group D
(n = 41)
VI & CVCs
p
value*
n (%)
Gender 0.917
Male 38 (36%) 5 (31%) 14 (40%) 4 (27%) 15 (37%)
Female 68 (64%) 11 (69%) 21 (60%) 10 (67%) 26 (63%)
Help to fill in questionnaires (self-report) 45 (42%) 1 (6%) 3 (9%) 9 (60%) 32 (78%) < 0.001
Mean ± SD
Age (years) 57 ± 12 47 ± 11 53 ± 10 54 ± 16 64 ± 9 < 0.001
BCVA Snellen (LogMAR) 20/125 (0.79 ± 0.67) 20/25 (0.11 ±
0.11)
20/32 (0.16 ±
0.16)
20/250 (1.10 ±
.056)
20/320 (1.24 ±
0.53)
< 0.001
Average no. of CVCs 1.61 ± 1.39 0 2.09 ± 1.12 0 2.41 ± 1.07 < 0.001
Duration of PXE (years) 17 ± 12 11 ± 10 18 ± 13 20 ± 14 18 ± 9 0.127
Functional IVI score 20.16 ± 8.16 28.12 ± 4.99 23.52 ± 6.62 20.99 ± 6.18 13.63 ± 5.99 < 0.001
Emotional IVI score 8.82 ± 3.24 10.75 ± 2.46 9.06 ± 3.11 10.63 ± 3.05 7.22 ± 2.98 < 0.001
Rasch guided SF-36 physical functioning
score
19.98 ± 7.58 23.21 ± 5.73 19.76 ± 8.02 16.93 ± 7.35 20.29 ± 7.58 0.141
Rasch guided SF-36 mental health score 14.48 ± 6.19 16.77 ± 6.04 13.91 ± 5.67 14.30 ± 5.93 14.35 ± 6.69 0.478
SD = Standard deviation; CVCs = cardiovascular complications; VI = Vision impairment; BCVA = Best corrected distance visual acuity. *ANOVA, testing for
difference between all groups.
Table 2 Fit parameters of the IVI (and subscales) and SF-36 scales compared to Rasch model requirements.
Parameters Rasch model IVI_O IVI_F IVI_E SF36_C SF-36_PF SF-36_MH
Disordered thresholds No Yes No No No No No
No. of misfitting items 0 4 0 140 1
Person Separation Index > 0.2 4.07 4.28 2.42 2.66 2.64 2.13
Person Reliability > 0.8 0.94 0.95 0.85 0.88 0.87 0.82
Person-item mean difference < 1 1.15 1.25 1.49 0.30 2.25 1.26
Variance by 1
st factor > 50% 64.2% 63.3% 63.1% 40.7% 68.2% 66.5%
PCA (Eigenvalue for 1
st contrast) < 2.4 3.9 2.4 1.8 8.3 2.3 2.2
Differential Item Functioning
Gender < 1.0 NA None None NA None None
Age group
(≤50, > 50)
< 1.0 NA None None NA None None
Vision impairment (VI, non-VI) < 1.0 NA None None NA None None
Participant person measure mean ± SD - NA 20.16 ± 8.16 8.82 ± 3.24 NA 19.98 ± 7.58 14.48 ± 6.19
Clinically meaningful cut-off - NA < -4.1, > 4.1 < -1.6, > 1.6 NA < -3.8, > 3.8 < -3.1, > 3.1
IVI_O = Impact of Vision Impairment Original; IVI_F = Impact of Vision Impairment Functional; IVI_E = Impact of Vision Impairment Emotional; PCA = Principle
Components Analysis; SD = Standard deviation; SF36_C = SF36 Complete; PF = Physical Functioning scale of the SF-36, MH = Mental Health scale of the SF-36;
NA = Not assessed; VI = Vision Impairment
Bolded cells indicate misfiting values compared to the Rasch model requirements
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ficulty of the IVI items. No DIF was found for age
group, gender or VI.
The Emotional Scale had adequate discriminant ability
and satisfied the requirements for unidimensionality.
One item (Item 21) displayed misfit (MNSQ 1.64 logits),
however, it was retained as deleting it did not improve
fit statistics and it captures important emotional
information, i.e. embarrassment caused by eyesight. No
DIF was found for age group, gender or VI. Again, the
targeting of this subscale suggested that patients in this
sample were of higher ability than the average item diffi-
culty of the IVI.
Psychometric properties of the SF-36
First, all eight conventional SF-36 subscales as well as
the conventional summary scores were tested using
Table 3 Model characteristics and differences between the four groups, after adjusting for age, gender, VI, number of
comorbidities other than CVCs, duration of PXE and help needed to fill in questionnaires (analysis of covariance).
Adjusted
mean/RC*
95% CI Significance of the model/
change*
Partial Eta
2+
Corrected
model
Groups A-D as a predictor within
the model
Functional IVI p < 0.001 0.812
+ 0.241
+
Group A (reference) 23.66 (20.92;
26.40)
Group B -1.89 (-4.91;
1.13)
0.216
Group C -5.60 (-9.19;
-2.01)
0.003
Group D -6.90 (-10.41;
-3.39)
< 0.001
Emotional IVI p < 0.001 0.662
+ 0.128
+
Group A (reference) 7.47 (5.97;
8.97)
Group B -0.33 (-1.88;
1.22)
0.777
Group C 1.94 (0.06;
3.82)
0.043
Group D 1.32 (-0.66;
3.31)
0.188
Rasch guided SF-36 Physical
Functioning
p = 0.086 0.187
+ 0.064
+
Group A (reference) 21.50 (15.51;
27.49)
Group B -2.34 (-8.66;
3.97)
0.461
Group C -6.03 (-13.49;
1.45)
0.111
Group D -0.81 (-8.70;
7.09)
0.839
Rasch guided SF-36 Mental
Health
p = 0.093 0.159
+ 0.044
+
Group A (reference) 16.28 (12.06;
20.50)
Group B -3.77 (-8.41;
0.87)
0.109
Group C -0.19 (-5.87;
5.49)
0.947
Group D -2.28 (-7.64;
3.09)
0.400
Presented are fully adjusted models including interactions between all variables.
Functional and emotional subscale scores of both the IVI and SF-36 contributed reciprocally and were also adjusted for.
RC = regression coefficient, *reported for the model/change of mean in groups compared to group A (reference); CI = Confidence interval; Group A = No
impairment; Group B = Only CVCs; Group C = Only VI; Group D = CVCs & VI; Bolded values indicate statistical significance;
+ Partial Eta
2 effect size: ≥0.01 small,
≥0.06 medium, ≥0.14 large effect[53]
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Rasch model. Thus we continued with Rasch analysis of
the overall item pool to arrive at Rasch guided subscales.
The overall SF-36 scale had no disordered thresholds
indicating that the number and clarity of response
options were appropriate. The PSI and PR values were
2.66 and 0.88, respectively, which indicates satisfactory
discriminant ability of the scale. Targeting of the scale
was also excellent (difference in person and item mean
0.30 logits). For the overall SF-36, there were four mis-
fitting items (Items 20, 21, 22, 35) and evidence of mul-
tidimensionality (PCA of the residuals < 50% and
unexplained variance in the first contrast of the resi-
duals 8.3). Deletion of misfitting items did not improve
any of the fit statistics. The standardized residual load-
ings of the SF-36 items were explored to assess whether
items were loading onto separate factors. Items pertain-
ing to functional and emotional well-being loaded as
separate subscales. Therefore, we fitted the physical
component domain (items 3a-3j, 4a-d, 7-8, 11a-d) and
mental component domain (items 5a-c, 6, 9a-h, 10, 11a-
d) of the SF-36 to the Rasch model. After assessing all
model fit statistics, the SF-36 was eventually split into a
10-item Physical Functioning scale (items 3a-3j) and a
5-item Mental Health scale (items 9b, c, d, f, h).
The Physical Functioning scale displayed satisfactory
discriminant ability and unidimensionality. However, the
targeting of this scale was not optimal with a mean dif-
ference between person and items of 2.25, suggesting
that this sample was much more able than the average
item difficulty of the scale. The Mental Health scale also
demonstrated adequate discriminant ability and unidi-
mensionality. One item displayed borderline misfit (Item
9 h ,M N S Q1 . 3 4 ) ;h o w e v e r ,s i n c er e m o v a lo ft h i si t e m
did not improve other fit statistics it was retained. No
DIF was found for gender, age group or VI for either
the physical functioning or mental health scales. These
results collectively show that the Functional and Emo-
tional IVI and Physical Functioning and Mental Health
SF-36 subscales are unidimensional, reliable and valid
scales to assess VRQoL and HRQoL, respectively, in this
population.
To facilitate the interpretation of the person measure
scores, they were recalibrated from a negative-positive
scale to range between 0 and 40 for the IVI functional
subscale, 0 and 16 for the IVI emotional subscale, 10
and 30 for the SF-36 physical functioning subscale and
5 and 30 for the SF-36 mental health subscale. These
values represent the minimum and maximum possible
summed values for each subscale. In linear regression
models, independent significant predictors of VRQoL
and HRQoL were considered to be clinically meaningful
if the confidence interval limits of their beta coefficients
were approximately half the standard deviation of the
overall mean. This is generally considered to be a useful
e s t i m a t eo fac l i n i c a l l ym e a n i n g f u ld i f f e r e n c e[ 3 4 , 3 5 ] .
The participants’ mean ± SD score and clinically mean-
ingful cut-offs for each of the four final scales are given
in Table 3.
Relationship between vision impairment, cardiovascular
complications and VRQoL/HRQoL
Functional and emotional IVI scores were lowest in
patients with VI and CVC (Group D, p = 0.001 and
0.049, respectively) compared to all other groups (Table
1). In adjusted regression models, the presence of VI
and CVC were significant predictors of visual function-
ing and emotional well-being compared to group A (no
VI and CVC) (partial Eta
2 0.812 and 0.662, respectively;
p < 0.001; Table 3). No association was however found
for the SF-36 Physical Functioning and Mental Health
scale scores (Table 3).
After controlling for age, gender, duration of PXE,
number of comorbidities other than CVCs, help needed
to fill in the questionnaires (as a surrogate measure of
disability) and self-reported general health; vision
impaired patients of groups C (-5.6; p = 0.003 and 0.019
compared to groups A & B, respectively) and D (-6.9; p
< 0.001 compared to groups A & B) reported poorer
vision-specific functioning than groups A (reference)
and B (-1.89) who did not have any VI. These results
also represent a clinically meaningful reduction of
vision-related functioning in vision-impaired PXE
patients based on our estimated cut-off values. No sig-
nificant difference was found for vision-specific func-
tioning and emotional well-being between groups C and
D (p = 0.388 and 0.413, respectively), despite the pre-
sence of CVCs in group D. Group B (-0.33) reported
poorer vision-specific emotional well-being compared to
groups C (1.94, p = 0.005) and D (1.32, p = 0.029,
group-wise comparison not shown in Table 3) despite
not being vision impaired. Vision-specific emotional
well-being did not differ between groups A and D (p >
0.05) and was slightly higher in group C compared to A
(p = 0.043). The SF-36 Physical Functioning and Mental
Health scores were not significantly different between
any of the groups (p > 0.05).
Discussion
We investigated the impact of PXE on VRQoL and
HRQoL in this sample. Our findings indicate a consider-
able and clinically meaningful impact on visual function-
ing and a moderate association with vision-specific
emotional well-being in PXE patients with VI, irrespec-
t i v eo ft h ep r e s e n c eo fC V C s .T h ei m p a c to nH R Q o L
was found to be minimal despite considerable concur-
rent cardiovascular disease in a large proportion of the
sample, indicating a larger impact of vision impairment
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sample.
The detrimental impact of VI on visual functioning
has been shown for a number of ocular conditions
[21,36,37] and systemic diseases with ocular complica-
tions[38,39] which is consistent with the main finding
from our study. Vision rehabilitation has been shown to
improve participation in activities of daily living in both
patients with primary ocular disease [40] and patients
with ocular complications from systemic diseases who
may sometimes also have severe additional impairments
[39,41,42]. Therefore, timely referral of patients for
visual rehabilitation is crucial for maintaining good
visual functioning and QoL.
The finding that PXE patients without VI had worse
vision-specific emotional well-being than those with VI
is seemingly contradictory. It may be due to the anxiety
experienced by non visually impaired PXE patients pre-
dicting the almost certain occurrence of ocular compli-
cations and the possibility of future bilateral blindness,
despite available treatment [1,43]. In patients with age-
related macular degeneration, the prospect of losing
vision in the first eye has been shown to lead to much
higher levels of anxiety and stress in newly affected
patients compared to a further loss of vision in the
remaining eye in patients at the more severe spectrum
of disease [37]. Similarly, studies in patients with dia-
betic retinopathy have found that those experiencing
recent disease progression and fluctuating vision report
more negative life events[44] and higher levels of psy-
chological distress, especially depression, than those
with worse yet stable vision [45]. These phenomena may
reflect differing levels of personal experience, better cop-
ing strategies and adaptation to disease progression and
level of VI in patients with long-standing VI [37]. In
addition, the unusual finding of better vision-specific
emotional well-being in patients with VI compared to
patients without VI may be partly due to patients with
VI having access to a highly specialized service including
personalized follow-up at the department of ophthal-
mology at the University of Bonn. Comprehensive low
vision rehabilitation programmes have repeatedly been
shown to improve not only functional ability but also
emotional well-being in visually impaired patients
[46-48]. Alternatively, this may in fact be a spurious out-
come due to our small sample size following stratifica-
tion. Therefore, future studies are needed to confirm
this finding.
No similarly specialised services within a clinic setting
dedicated to PXE are available to PXE patients with
CVCs in Germany. Access to such services has been
shown to improve the emotional well-being of patients
suffering from similar physical impairments. For exam-
ple, in a study of HRQoL in Ehlers-Danlos syndrome,
another rare disease of the connective tissue, patients’
emotional well-being as assessed by the SF-36, was
shown to be positively influenced by access to a highly
specialized service unit [49].
Given the rarity of PXE, having such a large sample of
patients with varying degrees of VI and general impair-
ment caused by cardiovascular disease, is a major
strength of this study. Further strengths include the use
of Rasch analysis, an important step in modern scale
validation, to assess the psychometric properties of the
German IVI and SF-36, and to produce estimates of
interval-level measurements of vision-specific function-
ing and emotional well-being, and general health-related
physical functioning and mental health. Use of both
scales provides a comprehensive assessment of the
impact of low vision and cardiovascular disease on
vision-specific and health-related QoL parameters. The
use of two QoL scales to assess the impact of multiple
impairments in this study is justified as only minimal
correlation has been found between VRQoL and
HRQoL scores [50,51]. Indeed, the results of this study
convincingly demonstrate the importance of using a
vision-specific outcome measure rather than a generic
HRQoL outcome measure to assess the impact of VI on
VRQoL. Generic patient-reported outcomes (PROs)
have very little vision-related content[52] and it is unli-
kely that any impact of VI on generic health-related
QoL will be successfully captured by these instruments.
Conversely, our study is limited by a sample size
which in general terms has to be considered small
which includes a high number of patients with no signif-
icant impairment and future studies would benefit from
a greater proportion of patients with low vision and/or
general disability. Use of Rasch analysis is appropriate
for smaller sample sizes as the response patterns on
which the analysis is based are not as easily skewed as
raw scores generated by classical test theory. Further-
more, selection of our sample may be biased due to a
response rate of 68%. However, respondents and non-
respondents did not seem to differ, and given the rarity
of PXE, larger studies are very difficult to conduct. The
use of the SF-36, a generic HRQoL measure rather than
a CVC specific measure, was felt justified as PXE is a
connective tissue disease leading to a broad range of
complications such as disfiguring skin changes, mobility
restriction, pain and gastrointestinal bleeding. We felt
that the impact of such a range of ailments could poten-
tially be better captured by a general HRQoL instrument
than a CVC-specific PRO measure. However, future stu-
dies that include measures of disability caused by cardi-
ovascular disease such as actual walking distance or
pain, as well as measures of anxiety and/or depression
may add to the understanding of the impact of PXE on
HRQoL.
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In conclusion, our novel study assessing the impact of
PXE on VRQoL and HRQoL demonstrates that there is
a significant impact on vision-specific functioning and
emotional well-being in PXE patients with and without
VI, irrespective of the presence of other CVCs. In con-
trast, little impact on general HRQoL was found. There-
fore, these results indicate that PXE patients would
benefit from specialized service provision focusing on
visual rehabilitation. Based on these findings, vision
impairment seems to have a larger impact than cardio-
vascular disease on reported QoL in PXE patients.
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